Table of Contents
<< Previous Issue | Mar 2015 (Vol: 2015, Issue: 3) | Next Issue >> |
- Section: Mergers & Acquisitions
-
Valeant Settles for Second Best with US$14.5 B Salix Acquisition
-
BMS Bets US$800 M Upfront That Flexus’ Preclinical IDO1 Inhibitor Is Best-in-Class
-
AbbVie Gambles US$21 B that Pharmacyclics’ Imbruvica® will Achieve Upside Potential
- Section: Opinion & Analysis
-
IMS PharmaDeals Review of 2014
- Section: Research & Development
-
Gene Therapy Start-Up Voyager Therapeutics Impresses with US$845 M Genzyme Deal